EMA Approves Factor VIII Deficiency Clotting Drug

European Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency.

Related Keywords

,European Medicines Agency ,European Commission ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Swedish Orphan Biovitrum ,Hemophilia Haemophilia ,Factor Viii ,Pain Management ,Europe ,European ,Blood ,Blood Vessels ,Back Pain ,Arthralgia ,Ainful Joint ,Joint Pain ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Fever ,Pyrexia ,Ebrile Response ,Genomics Genomic Medicine ,Hemorrhage ,Bleeding ,Spain ,Febrile Child ,Hild With Fever ,Pediatric Fever ,Prophylaxis ,Genetic Disorder ,Headache ,Healthcare And Medical Technology ,